# RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

> **NCT07114432** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 19 (estimated)

## Conditions studied

- Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT
- Newly Diagnosed Multiple Myeloma (NDMM)

## Interventions

- **DRUG:** BCMA/CD19-targeted allogeneic CAR-T

## Key facts

- **NCT ID:** NCT07114432
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-12
- **Final completion:** 2028-08
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07114432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07114432, "RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07114432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*